Abstract
BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 254-267 |
| Number of pages | 14 |
| Journal | Dermatologic Surgery |
| Volume | 45 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Surgery
- Dermatology
Cite this
Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma : A Retrospective Analysis From a Single Tertiary Academic Medical Center. / Trodello, Cameron; Higgins, Shauna; Ahadiat, Omeed; Ragab, Omar; In, Gino; Hawkins, Makenzie; Wysong, Ashley.
In: Dermatologic Surgery, Vol. 45, No. 2, 01.02.2019, p. 254-267.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma
T2 - A Retrospective Analysis From a Single Tertiary Academic Medical Center
AU - Trodello, Cameron
AU - Higgins, Shauna
AU - Ahadiat, Omeed
AU - Ragab, Omar
AU - In, Gino
AU - Hawkins, Makenzie
AU - Wysong, Ashley
PY - 2019/2/1
Y1 - 2019/2/1
N2 - BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.
AB - BACKGROUND Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and has potential for regional or distant metastasis. Despite the standardization of features associated with high-risk cSCC, an advanced subset of cSCC, there is no established consensus regarding proper management of this tumor.OBJECTIVETo evaluate the efficacy of cetuximab, add to existing management options, and aid in the development of standardized treatment for this tumor.MATERIALS AND METHODSMedical records were searched using Current Procedural Terminology codes for cetuximab and cSCC. Demographic data and tumor characteristics, along with treatment regimens and follow-up times, were collected. A total of 20 cases were examined.RESULTSOf the 20 cases, 3 experienced a complete response and 7 experienced a partial response, yielding an overall response of 50% and a combined median disease-free survival of 6.35 months (range 1-46.8 months).CONCLUSIONAs most of the patients who experienced a response received cetuximab as part of a multimodality treatment approach, cetuximab may be most efficacious when administered with concurrent therapies such as surgery or radiation. Further larger prospective studies to determine the optimal dosing and frequency of cetuximab and the utility of concurrent therapies are warranted.
UR - http://www.scopus.com/inward/record.url?scp=85061134240&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061134240&partnerID=8YFLogxK
U2 - 10.1097/DSS.0000000000001755
DO - 10.1097/DSS.0000000000001755
M3 - Article
C2 - 30672860
AN - SCOPUS:85061134240
VL - 45
SP - 254
EP - 267
JO - Dermatologic Surgery
JF - Dermatologic Surgery
SN - 1076-0512
IS - 2
ER -